Education
About Us
Working with TipRanks
Follow Us
ATAI Life Sciences (ATAI)
NASDAQ:ATAI
ATAI Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ATAI Stock 12 Month Forecast
Average Price Target
$11.14
▲(153.76% Upside)
| Highest Price Target$16.00 | Average Price Target$11.14 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$10→$15
Buy
241.69%
Upside
Reiterated
08/19/25
ATAI Life Sciences: Promising Outlook with Strategic Moves and Strong Financial PositionWe value atai Life Sciences using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology. We assign probabilities of success of 85% to to VLS-01. We model equity raises of $200M annually from 2026E-2029E to fund clinical and business development, which may dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. We value atai-owned programs at $14/share, and COMPASS at $1/share.
Maxim Group
$10
Buy
127.79%
Upside
Reiterated
08/15/25
TD Cowen
―
Buy
―
Reiterated
08/14/25
Oppenheimer
$16
Buy
264.46%
Upside
Initiated
07/29/25
Canaccord Genuity
$12→$11
Buy
150.57%
Upside
Reiterated
07/28/25
Aegis Capital
$8
Buy
82.23%
Upside
Reiterated
07/02/25
Jefferies
$5→$6
Buy
36.67%
Upside
Reiterated
07/01/25
Lucid Capital
$12
Buy
173.35%
Upside
Initiated
06/06/25
Unknown Analyst
Berenberg BankNot Ranked
Berenberg Bank
―
Buy
―
Initiated
04/03/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$10→$15
Buy
241.69%
Upside
Reiterated
08/19/25
ATAI Life Sciences: Promising Outlook with Strategic Moves and Strong Financial PositionWe value atai Life Sciences using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology. We assign probabilities of success of 85% to to VLS-01. We model equity raises of $200M annually from 2026E-2029E to fund clinical and business development, which may dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. We value atai-owned programs at $14/share, and COMPASS at $1/share.
Maxim Group
$10
Buy
127.79%
Upside
Reiterated
08/15/25
TD Cowen
―
Buy
―
Reiterated
08/14/25
Oppenheimer
$16
Buy
264.46%
Upside
Initiated
07/29/25
Canaccord Genuity
$12→$11
Buy
150.57%
Upside
Reiterated
07/28/25
Aegis Capital
$8
Buy
82.23%
Upside
Reiterated
07/02/25
Jefferies
$5→$6
Buy
36.67%
Upside
Reiterated
07/01/25
Lucid Capital
$12
Buy
173.35%
Upside
Initiated
06/06/25
Unknown Analyst
Berenberg BankNot Ranked
Berenberg Bank
―
Buy
―
Initiated
04/03/25
Best Analysts Covering ATAI Life Sciences
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+4.39%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +4.39% per trade.
3 Months
xxx
Success Rate
7/9 ratings generated profit
Average Return
+30.77%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +30.77% per trade.
1 Year
Success Rate
7/9 ratings generated profit
Average Return
+74.33%
reiterated a buy rating 8 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +74.33% per trade.
2 Years
xxx
Success Rate
8/9 ratings generated profit
Average Return
+85.73%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +85.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ATAI Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
7
10
20
17
Buy
2
3
2
3
3
Hold
4
8
8
11
8
Sell
0
2
2
2
0
Strong Sell
0
0
0
0
0
total
10
20
22
36
28
Each month's total comprises the sum of three months' worth of ratings.
ATAI Financial Forecast
ATAI Stock Forecast FAQ
What is ATAI’s average 12-month price target, according to analysts?
Based on analyst ratings, ATAI Life Sciences’s 12-month average price target is 11.14.
What is ATAI’s upside potential, based on the analysts’ average price target?
ATAI Life Sciences has 153.76% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ATAI a Buy, Sell or Hold?
ATAI Life Sciences has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is ATAI Life Sciences’s price target?
The average price target for ATAI Life Sciences is 11.14. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $6.00. The average price target represents 153.76% Increase from the current price of $4.39.
The highest analyst price target is $16.00 ,the lowest forecast is $6.00. The average price target represents 153.76% Increase from the current price of $4.39.
What do analysts say about ATAI Life Sciences?
ATAI Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of ATAI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.